Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.85 USD
+0.07 (9.10%)
Updated Mar 18, 2024 04:00 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Income Statements
Fiscal Year end for Sangamo Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 176 | 111 | 111 | 118 | 102 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 176 | 111 | 111 | 118 | 102 |
Selling & Adminstrative & Depr. & Amort Expenses | 450 | 313 | 294 | 248 | 208 |
Income After Depreciation & Amortization | -274 | -201 | -183 | -130 | -105 |
Non-Operating Income | 11 | 9 | 5 | 9 | 10 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -263 | -192 | -178 | -121 | -95 |
Income Taxes | -5 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -258 | -192 | -178 | -121 | -95 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -258 | -192 | -178 | -121 | -95 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -165 | -182 | -163 | -117 | -100 |
Depreciation & Amortization (Cash Flow) | 109 | 19 | 20 | 13 | 5 |
Income After Depreciation & Amortization | -274 | -201 | -183 | -130 | -105 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 174.44 | 154.35 | 144.57 | 134.45 | 112.11 |
Diluted EPS Before Non-Recurring Items | -0.59 | -1.25 | -1.23 | -0.90 | -0.85 |
Diluted Net EPS (GAAP) | -1.48 | -1.25 | -1.23 | -0.90 | -0.85 |
Fiscal Year end for Sangamo Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 | |
---|---|---|---|---|---|
Sales | 2.04 | 9.40 | 6.84 | 157.96 | 27.23 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 2.04 | 9.40 | 6.84 | 157.96 | 27.23 |
SG&A, R&D, and Dept/Amort Expenses | 64.11 | 115.81 | 130.41 | 139.93 | 82.62 |
Income After SG&A, R&D, and Dept/Amort Expenses | -62.07 | -106.41 | -123.57 | 18.03 | -55.39 |
Non-Operating Income | 1.49 | 3.52 | 2.80 | 3.29 | 3.68 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -60.57 | -102.89 | -120.77 | 21.33 | -51.71 |
Income Taxes | -0.27 | 1.27 | -6.26 | 0.19 | 0.26 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -60.30 | -104.16 | -114.51 | 21.13 | -51.97 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -60.30 | -104.16 | -114.51 | 21.13 | -51.97 |
Earnings Per Share Data | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 |
---|---|---|---|---|---|
Average Shares | 177.62 | 177.17 | 174.33 | 169.18 | 164.72 |
Diluted EPS Before Non-Recurring Items | -0.34 | -0.34 | -0.37 | 0.12 | -0.32 |
Diluted Net EPS (GAAP) | -0.35 | -0.59 | -0.66 | 0.12 | -0.32 |